Journal
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
Volume 33, Issue 11, Pages 1420-1426Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MEG.0000000000001882
Keywords
glycemic control; hepatic fibrosis; non-alcoholic fatty liver disease; steatosis; type 2 diabetes
Categories
Funding
- Region Stockholm
- Bengt Ihre Research Fellowship
- Swedish Gastroenterology Fund
- Ruth and Richard Julin Foundation
- Swedish Nutritional Foundation
- Tore Nilssons Foundation for Medical Research
- Ake Wiberg Foundation
- Swedish Society of Medicine
- Astra Zeneca
- Gilead
- Stockholm County Council [K2017-4579]
- Center for innovative medicine [CIMED 20180889]
- Swedish Cancer Society [170690]
- Intercept
Ask authors/readers for more resources
Improving glycemic control through a personalized treatment program is associated with a reduction in liver steatosis and stiffness in persons with advanced T2D.
Background and aims It is unclear if improving glycemic control in persons with type 2 diabetes (T2D) also has liver-related effects. We aimed to evaluate if a personalized treatment program associates with improvement of liver-related parameters in persons with advanced T2D in a real-life setting. Methods Persons with advanced T2D underwent a 4-day personalized treatment program, with the aim of improving glycemic control by dietary advice, instructions on how to achieve optimal glucose control and individualized dosage of medications. Transient elastography was used to estimate liver steatosis and fibrosis. Persons with liver diseases other than non-alcoholic fatty liver disease (NAFLD) were excluded. After 3 months, study participants were offered re-examination. Results Ninety-one persons were included. Of these, 75 persons (82%) had controlled attenuation parameter (CAP) measurements of acceptable quality at baseline. Of these, 57 (76%) had NAFLD (defined as >268 dB/m). Twenty-two persons (24%) had elevated liver stiffness (>7.9 kPa), and eight (9%) had liver stiffness above 13.9 kPa, indicating advanced fibrosis. Over a median follow-up of 101 days, mean CAP in persons with NAFLD was reduced by 18.33 dB/m (P = 0.035). In persons with elevated liver stiffness, mean stiffness was reduced by 2.6 kPa (P = 0.047). In linear regression, one-unit improvement in fasting glucose (mg/dl) was associated with a decrease in hepatic steatosis with 0.48 dB/m (adjusted R-2 = 0.35, P < 0.01). Conclusion The prevalence of NAFLD with advanced fibrosis is high in persons with advanced T2D. Improving glycemic control through a personalized treatment program is associated with a reduction in liver steatosis and stiffness in this cohort.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available